Interim data from a retrospective multicenter European study presented PET-based assessment as a faster way to detect early response to vorasidenib in IDH-mutant glioma. Using PET RANO 1.0 on amino-acid PET scans, investigators reported a higher partial response rate (29%) than MRI-based RANO 2.0 (6%), and a shorter median time to response (4 months vs 8 months). The study suggests metabolic tumor volume change drove early discrimination, reinforcing how amino-acid PET may capture pharmacodynamic effects before structural MRI shifts.